治疗慢性粒细胞白血病新药imatinib  

Breakthrough drug for chronic myeloid leukemia,imatinib

作　　者：赵戬[1] 

机构地区：[1]北京诺华制药有限公司,北京100004

出　　处：《中国新药杂志》2001年第10期732-735,共4页Chinese Journal of New Drugs

摘　　要：慢性粒细胞白血病 (CML)患者体内有异常染色体形成并产生BCR ABL融合蛋白 ,该融合蛋白能激活酪氨酸激酶 ,刺激细胞过度增生导致慢性粒细胞白血病的发生。imatinib(格列卫 )能特异性抑制BCR ABL ,抑制信号传导 ,减少细胞增生并使细胞凋亡 ,从而有效治疗慢性粒细胞白血病。Philadelphia chromosome formed may result in the g eneration of the fusion protein BCR ABL, a constitutively activated tyrosine ki nas e which then causes chronic myeloid leukemia (CML).Since tyrosine kinase activit y is essential in the transforming function of BCR ABL that stimulates cells pr oliferation,imatinib(Glivec),an inhibitor of the tyrosine kinase, blocks kinase activities and induces cell apoptosis. Thus it will be effective in the treatmen t of CML.

关 键 词：格列卫 酪氨酸激酶 慢性粒细胞白血病 CML 抗肿瘤药 

分 类 号：R979.1[医药卫生—药品]